头颈部癌症的遗传特征及其治疗意义
Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
机构信息
Wake Forest School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC.
Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA.
出版信息
Semin Radiat Oncol. 2018 Jan;28(1):2-11. doi: 10.1016/j.semradonc.2017.08.005.
Abstract
Large-scale sequencing studies of head and neck squamous cell carcinoma (HNSCC) have elucidated the genetic changes that characterize HNSCC. These findings have supported the development of therapeutic strategies that target key components of aberrant signaling pathways and immune dysregulation. Cumulative evidence suggests that these agents in combination with radiotherapy may have synergistic effects. This review highlights the predictive biomarkers that have been identified from HNSCC genomic studies and implications on the development of molecular-targeting agents that may effectively treat patients with HNSCC, especially when used in combination with radiation.
摘要
大规模的头颈部鳞状细胞癌（HNSCC）测序研究阐明了HNSCC 的遗传变化。这些发现支持了开发治疗策略的发展，这些策略针对异常信号通路和免疫失调的关键成分。累积的证据表明，这些药物与放疗联合使用可能具有协同作用。本综述强调了从 HNSCC 基因组研究中确定的预测生物标志物及其对分子靶向药物开发的影响，这些药物可能对头颈部鳞状细胞癌患者有效治疗，尤其是与放疗联合使用时。
相似文献
1
Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
Semin Radiat Oncol. 2018 Jan;28(1):2-11. doi: 10.1016/j.semradonc.2017.08.005.
2
mTOR co-targeting strategies for head and neck cancer therapy.
Cancer Metastasis Rev. 2017 Sep;36(3):491-502. doi: 10.1007/s10555-017-9688-7.
3
Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Future Oncol. 2014 May;10(6):1065-80. doi: 10.2217/fon.14.18.
4
Insights into metastatic roadmap of head and neck cancer squamous cell carcinoma based on clinical, histopathological and molecular profiles.
Mol Biol Rep. 2024 Apr 29;51(1):597. doi: 10.1007/s11033-024-09476-8.
5
Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.
Cancer Discov. 2015 Mar;5(3):239-44. doi: 10.1158/2159-8290.CD-14-1205. Epub 2015 Feb 2.
6
Leveraging Genomics for Head and Neck Cancer Treatment.
J Dent Res. 2018 Jun;97(6):603-613. doi: 10.1177/0022034518756352. Epub 2018 Feb 8.
7
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Expert Opin Ther Targets. 2015 Jun;19(6):795-805. doi: 10.1517/14728222.2015.1012157. Epub 2015 Feb 5.
8
Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Oncologist. 2017 Jun;22(6):680-693. doi: 10.1634/theoncologist.2016-0318. Epub 2017 May 15.
9
Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.
BMC Genomics. 2015 Sep 2;16(1):654. doi: 10.1186/s12864-015-1865-x.
10
MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Oncotarget. 2017 Feb 7;8(6):9911-9921. doi: 10.18632/oncotarget.14253.
引用本文的文献
1
In Silico Discovery of a Novel Potential Allosteric PI3Kα Inhibitor Incorporating 3-(2-Chloro-5-fluorophenyl)isoindolin-1-one to Target Head and Neck Squamous Cell Carcinoma.
Biology (Basel). 2025 Jul 21;14(7):896. doi: 10.3390/biology14070896.
2
Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy-a review.
Front Pharmacol. 2024 Jul 5;15:1410942. doi: 10.3389/fphar.2024.1410942. eCollection 2024.
3
VIRMA promotes the progression of head and neck squamous cell carcinoma by regulating mRNA and m6A levels.
Biomol Biomed. 2024 Sep 6;24(5):1244-1257. doi: 10.17305/bb.2024.10358.
4
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer.
Biomark Res. 2024 Mar 5;12(1):32. doi: 10.1186/s40364-024-00576-y.
5
Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Head Neck. 2024 May;46(5):1126-1135. doi: 10.1002/hed.27718. Epub 2024 Mar 1.
6
Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma.
Biomedicines. 2023 Dec 21;12(1):24. doi: 10.3390/biomedicines12010024.
7
Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy.
Front Oncol. 2023 Dec 18;13:1273516. doi: 10.3389/fonc.2023.1273516. eCollection 2023.
8
Angiopoietin-like 4 induces head and neck squamous cell carcinoma cell migration through the NRP1/ABL1/PXN pathway.
Cell Signal. 2023 Aug;108:110697. doi: 10.1016/j.cellsig.2023.110697. Epub 2023 May 9.
9
Targeted therapy for head and neck cancer: signaling pathways and clinical studies.
Signal Transduct Target Ther. 2023 Jan 16;8(1):31. doi: 10.1038/s41392-022-01297-0.
10
Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions.
J Oral Pathol Med. 2022 Jul;51(6):546-552. doi: 10.1111/jop.13303. Epub 2022 May 20.
本文引用的文献
1
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Int J Cancer. 2017 Sep 15;141(6):1215-1221. doi: 10.1002/ijc.30808. Epub 2017 Jun 21.
2
Advances in Radiation Oncology: What to Consider.
Otolaryngol Clin North Am. 2017 Aug;50(4):755-764. doi: 10.1016/j.otc.2017.03.011. Epub 2017 May 17.
3
Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
Clin Oral Investig. 2018 Jan;22(1):189-200. doi: 10.1007/s00784-017-2099-x. Epub 2017 Mar 18.
4
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Pharmacol Ther. 2017 May;173:83-105. doi: 10.1016/j.pharmthera.2017.02.008. Epub 2017 Feb 5.
5
Integrated genomic and molecular characterization of cervical cancer.
Nature. 2017 Mar 16;543(7645):378-384. doi: 10.1038/nature21386. Epub 2017 Jan 23.
6
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Oncotarget. 2017 Mar 28;8(13):22203-22217. doi: 10.18632/oncotarget.14729.
7
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.
Nat Genet. 2017 Feb;49(2):180-185. doi: 10.1038/ng.3757. Epub 2017 Jan 9.
8
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.
9
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
Lancet Oncol. 2017 Feb;18(2):202-211. doi: 10.1016/S1470-2045(16)30648-9. Epub 2016 Dec 18.
10
Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.
Nat Genet. 2016 Dec;48(12):1544-1550. doi: 10.1038/ng.3685. Epub 2016 Oct 17.
Zotero 插件